Barclays analyst Etzer Darout raised the firm’s price target on Nuvalent (NUVL) to $152 from $112 and keeps an Overweight rating on the shares after the company presented data from the Phase 1/2 ALKove-1 study of neladalkib in tyrosine kinase inhibitor pre-treated patients with advanced ALK-positive non-small cell lung cancer.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Nuvalent rises 15.8%
- Nuvalent price target raised to $135 from $115 at Stifel
- Nuvalent price target raised to $149 from $140 at Leerink
- Nuvalent’s Neladalkib: Promising ALK+ NSCLC Treatment with Strong Phase 2 Data and De-risked Approval Path
- Nuvalent’s Promising Future: Buy Rating Backed by ALKOVE-1 Study Success and Strategic Growth Plans